ENANTA PHARMACEUTICALS INC's ticker is ENTA and the CUSIP is 29251M106. A total of 117 filers reported holding ENANTA PHARMACEUTICALS INC in Q1 2015. The put-call ratio across all filers is 2.69 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2020 | $57,000 | -51.7% | 1,114 | -23.6% | 0.00% | – |
| Q1 2018 | $118,000 | +413.0% | 1,458 | +125.0% | 0.00% | – |
| Q3 2015 | $23,000 | -14.8% | 648 | +6.4% | 0.00% | – |
| Q2 2015 | $27,000 | -95.4% | 609 | -94.8% | 0.00% | -100.0% |
| Q4 2014 | $591,000 | +620.7% | 11,613 | +461.6% | 0.00% | – |
| Q3 2014 | $82,000 | -14.6% | 2,068 | -7.2% | 0.00% | – |
| Q2 2014 | $96,000 | -5.0% | 2,228 | -11.8% | 0.00% | – |
| Q1 2014 | $101,000 | -67.4% | 2,525 | -81.4% | 0.00% | -100.0% |
| Q3 2013 | $310,000 | -23.8% | 13,546 | -41.0% | 0.00% | 0.0% |
| Q2 2013 | $407,000 | – | 22,972 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Krensavage Asset Management, LLC | 564,102 | $42,184,000 | 14.63% |
| Fairmount Funds Management LLC | 387,400 | $28,970,000 | 9.55% |
| Soleus Capital Management, L.P. | 318,275 | $23,801,000 | 2.38% |
| Darwin Global Management, Ltd. | 166,190 | $12,428,000 | 1.90% |
| Paradigm Biocapital Advisors LP | 75,507 | $5,646,000 | 1.61% |
| ARMISTICE CAPITAL, LLC | 1,056,000 | $78,968,000 | 1.29% |
| KINGDON CAPITAL MANAGEMENT, L.L.C. | 150,000 | $11,217,000 | 1.29% |
| Portland Global Advisors LLC | 75,869 | $5,673,000 | 0.95% |
| FARALLON CAPITAL MANAGEMENT LLC | 1,573,829 | $117,691,000 | 0.59% |
| Yorktown Management & Research Co Inc | 10,400 | $778,000 | 0.52% |